免疫衰老和炎症对免疫检查点抑制剂效果的影响

Cancer pathogenesis and therapy Pub Date : 2024-01-01 DOI:10.1016/j.cpt.2023.08.001

Chuandong Hou , Zining Wang , Xuechun Lu

{"title":"免疫衰老和炎症对免疫检查点抑制剂效果的影响","authors":"Chuandong Hou , Zining Wang , Xuechun Lu","doi":"10.1016/j.cpt.2023.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells. Although ICIs can potentially treat different types of cancers in various groups of patients, their effectiveness may differ among older individuals. The reason ICIs are less effective in older adults is not yet clearly understood, but age-related changes in the immune system, such as immunosenescence and inflammation, may play a role. Therefore, this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000484/pdfft?md5=de94deaec420e00e46c23da7252d8e24&pid=1-s2.0-S2949713223000484-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors\",\"authors\":\"Chuandong Hou , Zining Wang , Xuechun Lu\",\"doi\":\"10.1016/j.cpt.2023.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells. Although ICIs can potentially treat different types of cancers in various groups of patients, their effectiveness may differ among older individuals. The reason ICIs are less effective in older adults is not yet clearly understood, but age-related changes in the immune system, such as immunosenescence and inflammation, may play a role. Therefore, this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.</p></div>\",\"PeriodicalId\":93920,\"journal\":{\"name\":\"Cancer pathogenesis and therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949713223000484/pdfft?md5=de94deaec420e00e46c23da7252d8e24&pid=1-s2.0-S2949713223000484-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer pathogenesis and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949713223000484\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer pathogenesis and therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949713223000484","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

免疫检查点抑制剂（ICIs）可用于免疫治疗，治疗免疫力低下的患者，并能提高 T 细胞杀死癌细胞的能力。虽然 ICIs 可以治疗不同患者群体的不同类型癌症，但其疗效在老年人中可能有所不同。ICIs 对老年人疗效较差的原因尚不清楚，但与年龄有关的免疫系统变化（如免疫衰老和炎症）可能是其中的一个原因。因此，本综述将重点介绍在了解免疫衰老和炎症对 ICIs 药效的影响方面取得的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors

查看原文本刊更多论文

Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for patients with weakened immune systems and can improve the ability of T cells to kill cancer cells. Although ICIs can potentially treat different types of cancers in various groups of patients, their effectiveness may differ among older individuals. The reason ICIs are less effective in older adults is not yet clearly understood, but age-related changes in the immune system, such as immunosenescence and inflammation, may play a role. Therefore, this review focuses on recent advances in understanding the effects of immunosenescence and inflammation on the efficacy of ICIs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer pathogenesis and therapy Surgery, Radiology and Imaging, Cancer Research, Oncology

CiteScore

0.80

自引率

0.00%

发文量

审稿时长

54 days